Tigecycline as effective as vancomycin plus aztreonam in the treatment of complicated skin and skin structure infections: Experience in Latin America;Tigeciclina versus vancomycin más aztreonam en el tratamiento de infecciones complicadas de piel y tejidos blandos: Experiencia en Latinoamérica

Revista Chilena de Infectologia

Volumn 26, Issue SUPPL. 1, 2009, Pages 23-31

  Campos B, M Isabel ^a   Curcio J, Daniel ^b   Seas R, Carlos ^c   Jasovich, Abel ^d   Northland G, Rebeca ^e   Arathoon P, Eduardo ^f   Rodríguez N, Eduardo ^g   Ellis Grosse J, Evelyn ^h   Loh, Evan ^h   Cooper H, Angel ^h  

^a Hospital de Urgencia Asistencia Pública Doctor Alejandro del Rio   (Chile)

^b Sanatorio Guemes   (Argentina)

^c HOSPITAL NACIONAL CAYETANO HEREDIA   (Peru)

^d Hospital Carlos Bocalandro   (Argentina)

^e Department of Oral and Maxillofacial Surgery   (Chile)

^f Hospital General San Juan de Dios   (Guatemala)

^g HOSPITAL CIVIL DE GUADALAJARA FRAY ANTONIO ALCALDE   (Mexico)

^h PFIZER INC   (United States)

Author keywords

Aztreonam; Efficacy; Safety; Skin structure infection; Tigecycline; Vancomycin

Indexed keywords

EID: 67650921958     PISSN: 07161018     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Nichols R L, Florman S. Clinical presentations of soft-tissue infections and surgical site infections. Clin Infect Dis 2001; 33 Suppl 2: S84-93.
2. Mallick R, Solomon S. Global variations in infection diagnoses, etiology, co-morbidities, and causative microbiology in hospitalized patients with complicated skin and skin structure infections (CSSSI): evidence from a pooled clinical database. European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Copenhagen, Denmark. Apr 2-5 2005.
3. Stevens D L, Bisno A L, Chambers H F, Everett E D, Dellinger P, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005; 41: 1373-406.
4. DiNubile M J, Lipsky B A. Complicated infections of skin and skin structures: when the infection is more than skin deep. J Antimicrob Chemother 2004; 53 Suppl 2: ii37-50.
5. Jones M E, Karlowsky J A, Draghi D C, Thornsberry C, Sahm D F, Nathwani D. Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapy. Int J Antimicrob Agents 2003; 22: 406-19.
6. Jones R N. Global epidemiology of antimicrobial resistance among communityacquired and nosocomial pathogens: a fiveyear summary from the SENTRY antimicrobial surveillance program (1997-2001). Semin Respir Crit Care Med 2003; 24: 121-34.
7. Gales A C, Jones R N, Pfaller M A, Gordon K A, Sader H S. Two-year assessment of the pathogen frequency and antimicrobial resistance patterns among organisms isolated from skin and soft tissue infections in Latin American hospitals: results from the SENTRY antimicrobial surveillance program, 1997-98. SENTRY Study Group. Int J Infect Dis 2000; 4: 75-84.
8. Sader H S, Jones R N, Silva J B, Group S P. Skin and soft tissue infections in Latin American medical centers: four-year assessment of the pathogen frequency and antimicrobial susceptibility patterns. Diagn Microbiol Infect Dis 2002; 44: 281-8.
9. Bantar C, Famiglietti A, Goldberg M. Three-year surveillance study of nosocomial bacterial resistance in Argentina. The Antimicrobial Committee; and the National Surveillance Program (SIR) Participants Group. Int J Infect Dis 2000; 4: 85-90.
10. Jones C H, Petersen P J. Tigecycline: First class glycylcycline. A new choice for empiric therapy. Drug Discovery Today: Therapeutic Strategies 2006; 3: 137-44.
11. Noskin G A. Tigecycline: A new glycylcycline for treatment of serious infections. Clin Infect Dis 2005; 41 (5 Suppl): S303-S314.
12. Pankey G A. Tigecycline. J Antimicrob Chemother 2005; 56 (3): 470-80.
13. Hoban D J, Bouchillon S K, Johnson B M, Johnson J L, Dowzicky M J; Tigeclycline Evaluation and Surveillance Trial Group (TEST Program). In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). Diagn Microbiol Infect Dis 2005; 52: 215-27.
14. Bradford P, Weaver-Sands D T, Petersen P J. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials for complicated skin and skin structure infections and complicated intra-abdominal infections. Clin Infect Dis 2005; 41: S315-32.
15. Breedt J, Teras J, Gardovskis J, Maritz F J, Vaasna T, Ross D P, et al. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother 2005; 49: 4658-66.
16. Ellis-Grosse E J, Babinchak T, Dartois N, Rose G, Loh E. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 doubleblind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005; 41 Suppl 5: S341-53.
17. Sacchidanand S, Penn R L, Embil J M, Campos M E, Curcio D, Ellis-Grosse E, et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial. Int J Infect Dis 2005; 9: 251-61.
18. Clinical Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing: M100-S15, fifteenth informational supplement. Wayne, PA: Clinical Laboratory Standards Institute; 2005.
19. Zinner S H. Overview of antibiotic use and resistance; Setting the stage for tigecycline. Clin Infect Dis 2005; 41: S289-92.
20. Spellberg B, Powers J H, Brass E P, Miller L G, Edwards J E, Jr. Trends in antimicrobial drug development: implications for the future. Clin Infect Dis. 2004; 38: 1279-86.
21. Gales A C, Jones R N, Andrade S S, Pereira A S, Sader H S. In vitro activity of tigecycline, a new glycylcycline, tested against 1,326 clinical bacterial strains isolated from Latin America. Braz J Infect Dis 2005; 9: 348-56.